Coming on the back of a Regeneron research piece published in the New England Journal of Medicine, the company announced a link up with Alnylam to work on the discovery it had made in the potential development of a treatment for non-alcoholic steatohepatitis (NASH).
The research discovered that a variant of the HSD17B13 gene, which was found to be associated with a reduced risk of chronic liver disease.
Original Article: Regeneron-Alnylam team up to treat NASH
NEXT ARTICLE